Extractables & Leachables

Including: Important Regulatory Updates – Case Study Section: Selection of the most interesting Case Studies, presented over the last 10 years!

Overview

When making Parenteral Drug Products, pharmaceutical companies are faced with the need to further investigate the materials that will be in contact with the drug product, either during manufacturing, intermediate storage, storage in its final packaging, or during the delivery of the drug to the patient. While historically, the potential safety issues were the main driver in these kinds of investigations, recently, also quality issues – i.e. for biopharmaceuticals – have become an additional concern. This workshop will look at "Extractables & Leachables" from many different angles: Definitions, Regulatory, Material & Polymer Science, Analytical E/L Methodologies, Safety Assessments, Study Design for different parenteral primary packaging systems, as well as for injection devices.

Learning Objectives

Upon completion of this workshop, you will be able to:

- Explain in detail the current regulatory requirements for container/closure qualification from an E/L perspective.
- Explain the upcoming changes in regulations, standards and recommendations from PQRI, USP and BPOG and how these changes could impact a future evaluation of a pharmaceutical C/C-system.
- Understand the materials of construction and their composition – of container closure systems, and how they could impact the safety and quality of a parenteral drug product.
- Put together an evaluation program (review of provided documentation, analytical testing) of different types of parenteral drug product container/closure systems.
- Perform a safety/risk assessment of analytical results, obtained after completion of an E/L study.

Who Should Attend

- Pharmaceutical Packaging and Device Engineers
- Production Engineers, using SU systems
- Regulatory Affairs Officers
- Pharmaceutical R & D Managers
- Analytical Chemists, working on E/L
- Quality Assurance Officers



Dennis Jenke, PhD, Chief Executive Scientist, Triad Scientific Solutions

Dennis Jenke is the Chief Executive Scientist for Triad Scientific Solutions, a provider of science-based solutions to plastic/product compatibility challenges associated with packaging, manufacturing equipment and delivery devices in the pharmaceutical, cosmetic, food and related industries. He was a Distinguished Scientist at Baxter Healthcare Corporation where for more than three decades he lead a team whose primary responsibility includes the assessment of material/product compatibility, specifically with respect to

establishing the suitability for use of packaging systems, manufacturing systems and administration devices for pharmaceutical products (for example, extractables/leachables and product ingredient binding). He has published extensively in the areas of analytical chemistry, environmental science and material/solution compatibility and serves as an expert reviewer for numerous pharmaceutical and analytical journals. He is the author of the book Compatibility of Pharmaceutical Solutions and Contact Materials; Safety Considerations Associated with Extractables and Leachables and a contributing author to the Leachables and Extractables Handbook. Dennis Jenke is a member of numerous industry groups whose charter is to establish best demonstrated practices in the area of material/solution compatibility.

Thursday, 29 November 2018

9:00 - 18:00

Introduction on Extractables & Leachables (E/L)

- ▶ What is the importance of a good E/L-qualification
- ► Historical cases of leachables, impacting the quality or the safety of a drug product
- ► Regulatory requirements (FDA, EMA...) for primary packaging

Understanding the Materials, Used in the Manufacture of Pharmaceutical Containers & Closures

- ► Types of polymers examples in medical/pharmaceutical use
- ► Understanding the composition of polymers
- ► The issues with glass in parenteral applications

FULL Session on Updates of E/L- Regulations, Standards and Recommendations

- ► Pharma Packaging:
 - Preview of the final PQRI Parenteral Drug Product (DPD) & ODP Chemistry group
 - Update on the most recent developments on the USP <661> chapters
- ▶ Devices
 - Chemical characterization of devices according to ISO 10993-18: What changes are coming up?
 - Upcoming Revisions of the USP <87> and USP <88>: Where could it go to?
- ► (Bio)Pharmaceutical Manufacturing
 - Where is USP with the update on the USP <661.3> Plastic Manufacturing Components standard

How to Perform a Safety Evaluation – Risk Assessment on Extractables & Leachables

- ► Toxicology 101
- ► EMA Guideline on Genotoxic Impurities
- ► ICH M7 (DNA reactive Impurities) and its suggested staged approach
- ► The Threshold Concept of PQRI (OINDP and PDP/ODP)
- ► Examples

How to Look at Injection Devices from an E/L Perspective

- ► Medical device regulations versus pharma packaging
- ► Test selection process for devices: What to do?
- ▶ USP and ISO 10993 series for biocompatibility testing
- ► Case: Injection device



Piet Christiaens, PhD, Scientific Director, Nelson Labs NV

Piet Christiaens received his Ph.D. from the Analytical Chemistry Department of the University of Leuven (Belgium) in 1991. From 1992 to 1997, he was Lab Manager in two Analytical Contract Laboratories. From 1997 to 2000, he worked as an independent consultant with Shell Chemical Company in Houston, Texas where he conducted research on a new hydrogenation catalyst system for Hydrogenated Triblock Co-Polymers (Kraton Polymers). Since 2001, Mr. Christiaens has been Scientific Director developing analytical methods and pro-

tocols for both extractables and leachables studies for the Medical and Pharmaceutical Industries. Mr. Christiaens oversees all laboratory operations at Nelson Labs Europe and supports the European business development team.

Friday, 30 November 2018

9:00 - 16:30

E/L Testing for Small Volume Parenteral Applications

- ▶ Glass Syringes: the issues with tungsten, glue residues and silicone oil and glass metals leaching
- ▶ The Issue with rubbers: the plunger, the needle shield or the tip cap: different approaches needed?
- ► The impact of secondary packaging option or necessity?
- ▶ Setting up extractable & leachable studies for a pre-filled Syringe or a vial system

E/L Testing for Lyophilized Drug Products

- ▶ Primary packaging for the lyophilized drug product modus of interaction with the DP
- ▶ Impact of the "21CFR Part 4" on combination products, used in the administration of a lyo DP
- ► Critical aspects when designing leachable studies for lyophilized DP
- ▶ Integration of the administration procedure (e.g. IV-set, pump system) in leachables evaluation

Large Volume Parenterals

- ► The challenge in E/L testing for LVP's
- ▶ Primary packaging for LVP's critical materials and components
- Secondary packaging for LVP: critical points to consider

E/L Testing for Disposable and Single-Use Systems in Bioproduction

- ▶ How to classify the risk of different single-use systems in the bioproduction process
- ▶ Understanding BPSA & BPOG recommendations, and how they can be implemented in the study design
- ► Performing E/L studies on filters: potential approaches

Analytical Techniques and Methodologies in E/L Research

- ▶ Discussion of the Analytical Instrumentation used
- ▶ The Analytical Chromatographic Screening Process to Discover, Identify and Quantify Organic Extractables
- ► The Risk of Omissions with the Screening Process
- ▶ The Risk of Inexact Identifications in the Screening Process
- ► The Risk of Inaccurate Quantification when Sscreening
- ► A Risk Mitigation Strategy when Implementing a Screening Methodology

How to Set-up Extractables & Leachables Studies

- ► Selecting the right conditions for extraction
- ► How to select the right compounds to monitor in a leachable study
- ► Designing a leachable study



John Iannone, Principal Consultant, iCG Solutions

John Iannone has a background in Biomedical Engineering from Boston University. Since joining the Biotech/ Medtech Industry 15 years ago, John has assisted multiple pharmaceutical & medical device companies with the development of their product safety evaluation strategies. Currently he is a Principal Consultant for iCG, LLC. His areas of expertise include Material Qualification & Biocompatibility, Extractables & Leachables, Chemical Characterization, and attainment of Biological or Toxicological risk assessments for medical devices, pharmaceutical container systems, bioprocessing systems, and combination products. John has given

numerous technical presentations and has led many workshops on Extractable & Leachable Considerations, Biocompatibility, Microbiology, and Regulatory Testing Requirements. He also participates in the development of both industry groups' recommendations and regulatory guidelines through Expert Panel membership, global Technical Committees, and industry collaborations.